| Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019 | 3023 | 2019 |
| Integrating feedback from a clinical data warehouse into practice organisation A Grant, A Moshyk, H Diab, P Caron, F de Lorenzi, G Bisson, L Menard, ... International journal of medical informatics 75 (3-4), 232-239, 2006 | 67 | 2006 |
| Depression and mortality in the visually‐impaired, community‐dwelling, elderly population of Quebec M Tournier, Y Moride, T Ducruet, A Moshyk, S Rochon Acta ophthalmologica 86 (2), 196-201, 2008 | 47 | 2008 |
| Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada A Moshyk, MJ Martel, AA Tahami Monfared, R Goeree Journal of medical economics 19 (2), 191-202, 2016 | 30 | 2016 |
| Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 MM Regan, CM Mantia, L Werner, AA Tarhini, J Larkin, FS Hodi, ... Journal for immunotherapy of cancer 9 (11), 2021 | 21 | 2021 |
| Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada P Quon, HH Le, V Raymond, M Mtibaa, A Moshyk Journal of medical economics 19 (6), 557-567, 2016 | 21 | 2016 |
| When is bioavailable testosterone a redundant test in the diagnosis of hypogonadism in men? I Gheorghiu, A Moshyk, R Lepage, CE Ahnadi, AM Grant Clinical biochemistry 38 (9), 813-818, 2005 | 21 | 2005 |
| Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis K Toor, MR Middleton, K Chan, A Amadi, A Moshyk, S Kotapati BMC cancer 21, 1-11, 2021 | 20 | 2021 |
| A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆ AA Tarhini, K Toor, K Chan, DF McDermott, P Mohr, J Larkin, FS Hodi, ... ESMO open 6 (2), 100050, 2021 | 20 | 2021 |
| Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors E Coart, S Suciu, P Squifflet, ED Saad, A Moshyk, G de Schaetzen, ... European Journal of Cancer 137, 171-174, 2020 | 15 | 2020 |
| Real-world systemic therapy treatment patterns for squamous cell carcinoma of the head and neck in Canada K Byrne, P Hallworth, A Monfared, A Moshyk, JW Shaw Current oncology 26 (2), 167-174, 2019 | 14 | 2019 |
| Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma R Potluri, S Ranjan, H Bhandari, H Johnson, A Moshyk, S Kotapati Experimental Hematology & Oncology 8, 1-10, 2019 | 13 | 2019 |
| Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from … S Branchoux, CL Sofeu, AF Gaudin, M Kurt, A Moshyk, A Italiano, ... ESMO open 7 (1), 100340, 2022 | 12 | 2022 |
| Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma JS Weber, PA Ascierto, MR Middleton, D Hennicken, R Zoffoli, A Pieters, ... European Journal of Cancer 158, 225-233, 2021 | 11 | 2021 |
| Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study S Dalle, L Mortier, P Corrie, M Lotem, R Board, AM Arance, F Meiss, ... Bmc Cancer 21 (1), 642, 2021 | 11 | 2021 |
| Reflections on an arranged marriage between bioinformatics and health informatics AM Grant, AM Moshyk, A Kushniruk, JR Moehr Methods of information in medicine 42 (02), 116-120, 2003 | 10 | 2003 |
| Cost–utility analysis of nivolumab in adjuvant treatment of melanoma in France B Bregman, S Teitsson, I Orsini, FE Cotté, A Amadi, A Moshyk, S Roze, ... Dermatology and therapy 10, 1331-1343, 2020 | 9 | 2020 |
| Heterogeneity in survival with immune checkpoint inhibitors and its implications for survival extrapolations: a case study in advanced melanoma V Federico Paly, M Kurt, L Zhang, MO Butler, O Michielin, A Amadi, ... MDM Policy & Practice 7 (1), 23814683221089659, 2022 | 8 | 2022 |
| An informatics perspective on decision support and the process of decision-making in health care A Grant, A Kushniruk, A Villeneuve, N Bolduc, A Moshyk Using knowledge and evidence in health care: multidisciplinary perspectives …, 2004 | 8 | 2004 |
| Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY … D Schadendorf, H Tawbi, EJ Lipson, FS Hodi, P Rutkowski, H Gogas, ... European Journal of Cancer 187, 164-173, 2023 | 7 | 2023 |
